General Range
FORIXONE-250
Price on request/100 · MOQ 100 boxes
FORIXONE-250 Injection by Fortune Labs contains Ceftriaxone 250 mg, a third-generation cephalosporin antibiotic used to treat infections caused by susceptible bacteria. Ceftriaxone works by inhibiting bacterial cell wall synthesis, helping eliminate infection-causing microorganisms. FORIXONE-250 may be prescribed for selected respiratory tract infections, urinary tract infections, skin infections, and other bacterial conditions when clinically appropriate. Suitable for intravenous or intramuscular administration by qualified healthcare professionals, this formulation is supplied in a 250 mg single-dose vial. FORIXONE-250 is part of Fortune Labs' injectable pharmaceutical portfolio. Fortune Labs offers Injection PCD Pharma Franchise and distribution opportunities across India. Contact Fortune Labs for wholesale pricing, product availability, monopoly franchise opportunities, and business enquiries. Use strictly under medical supervision.
CategoryGeneral Range
Min. Order100 boxes
Supplied byFortune Labs
CertificationWHO-GMP, ISO
Prices are indicative and set by the listing company. Confirm net rates, packing and stock availability directly with the supplier.
Specifications
- Composition
- Ceftriaxone 250 mg
- Packaging Type
- Glass Vial with Outer Carton
- Packaging Size
- 250 mg Single-Dose Vial
- Dosage Form
- Injectable Solution
- Treatment
- Bacterial respiratory tract infections, pneumonia, urinary tract infections, skin and soft tissue infections, meningitis, and other infections caused
- Shelf Life
- 24 Months
- Storage
- Store below 30°C, protect from light & moisture
- Certification
- WHO-GMP, ISO
Company Info
Fortune LabsPanchkula, Haryana
Fortune Labs is an Indian pharmaceutical and PCD (Propaganda Cum Distribution) pharma franchise company based in Panchkula, Haryana.
Key Details
• Headquarters: S.C.F 258, 1st Floor, Sector 16, Panchkula, Haryana, India
• Establishment: Founded in 2008 (sister concern of Prosperity 6 Pharmaceutics in Baddi)
• CEO / Leadership: Mayank Bansal
• Certifications: ISO 9001, WHO-GMP, and DCGI-approved formulations
• Business Model: Offers Pan-India PCD pharma franchises with monopoly rights, third-party manufacturing, and marketing support.
Product Portfolio & Therapeutic Ranges
• Formulations: Tablets, capsules, syrups, dry powders, injectables, ointments, gels, eye/ear/nasal drops, softgel capsules, and Ayurvedic/herbal products.
• Therapeutic Segments: Antibiotics, cardiac and diabetic care, orthopedics, dermatology, gynaecology, paediatrics, gastrointestinal/PPI ranges, neurology, antihistamines/cough-cold, and nutritional supplements.
Would you like information on how to apply for a franchise partnership or specific product price lists from Fortune Labs?
More General Range
